An observational study in Porphyrias, Hepatic, sponsored by National Institute of Cardiology, Warsaw, Poland. Completed at 2 sites in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational
This study aims to assess the changes in the cardiovascular system in patients with acute intermittent porphyria (AIP).
Porphyrias are heterogeneous group of the disorders of heme biosynthesis. Acute intermittent porphyria (AIP) is the most common acute hepatic porphyria, caused by the mutations in the gene encoding hydroxymethylbilane synthase. Clinical symptoms i.e. abdominal pain, nausea, vomiting, paresis or paralysis, coma and/or mental abnormalities may be induced by many porphyrinogenic factors, such as drugs, alcohol, starvation or stress. The symptoms are often accompanied by tachycardia and elevated blood pressure. Due to the non-specific clinical picture, AIP is often diagnosed too late and causes a threat to the patients' lives.
There is a scarcity of data regarding the changes in cardiovascular system in patients with AIP. The aim of this study is to assess the structure and function of heart in patients with this disease. The prevalence of hypertension, cardiac arrhythmias and selected cardiovascular risk factors in patients with AIP will also be evaluated.
This is a case-control study with prospective observation of the subgroup of patients examined during the exacerbations of AIP.
Specific goals:
33 studies on the registry are indexed under Porphyria, Erythropoietic; 1 is open to participants now.
This study's enrollment of 180 is above the median of 110 across 14 observational studies indexed under Porphyria, Erythropoietic.
Browse Porphyria, Erythropoietic studies →National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 53 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patients with acute intermittent porphyria (AIP) meeting the eligibility criteria and people from the general population, matched by age, sex and body mass index.
Exclusion Criteria:
Patients aged 18-65 (men and women) with acute intermittent porphyria and at least one episode of exacerbation of this disease requiring admission to the hospital
People recruited from the general population and matched by age, sex and body mass index.
Number of participants with heart failure and left ventricular dysfunction.
Heart failure and left ventricular dysfunction assessed by symptoms and echocardiography.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Number of participants with hypertension.
Arterial hypertension diagnosed by ambulatory 24-hour blood pressure monitoring.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Rate of cardiac arrhythmias.
Cardiac arrhythmias observed in 24-hour ECG monitoring.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Number of participants with increased concentrations of markers of heart failure.
Concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) \> 125 pg/mL in serum.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Number of participants with increased concentrations of markers of myocardial injury.
Concentration of high sensitivity troponin T \> 14 ng/L in serum.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Number of participants with chronic kidney disease.
Renal function defined by estimated glomerular filtration rate based on the concentrations of creatinine in serum.
Time frame: day 1 and up to 2 years in case of the exacerbation of AIP
Number of participants with dyslipidemia.
Dyslipidemia defined as the concentrations of total cholesterol \> 190 mg/dL, low density lipoprotein (LDL) cholesterol \> 115 mg/dL, high density lipoprotein (HDL) cholesterol \< 48 mg/dL (female), \< 40 mg/dL (male), triglycerides \> 150 mg/dL.
Time frame: day 1
Number of participants with diabetes.
Diabetes in anamnesis or the concentration of glycated hemoglobin \> 6.5%.
Time frame: day 1
Level of quality of life.
Physical and mental components defined by the Short Form 36 survey (SF36). Answers are weighted and transformed into scores in a scale ranging from 0 (the lowest possible level of functioning) to 100 (no restrictions).
Time frame: day 1
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Porphyria, Acute Intermittent
National Institute of Cardiology, Warsaw, Poland